

O=S1C(=N2C(=N1)N(B)CN2)N(A)CN1 (IA)

A is selected from the group consisting of:

Chemical structures 1-12 are shown, representing various heterocyclic and fused ring systems with substituents R^7 , R^8 , and R^9 .

Structure 1: A benzene ring with a nitrogen atom at the 1-position, substituted with R^7 and R^8 at the 2-position, and a wavy line at the 3-position.

Structure 2: A benzene ring with a nitrogen atom at the 1-position, substituted with R^7 and R^8 at the 2-position, and a wavy line at the 3-position.

Structure 3: A benzene ring with a nitrogen atom at the 1-position, substituted with R^7 and R^8 at the 2-position, and a wavy line at the 3-position.

Structure 4: A benzene ring with a nitrogen atom at the 1-position, substituted with R^7 and R^8 at the 2-position, and a wavy line at the 3-position.

Structure 5: A benzene ring with a nitrogen atom at the 1-position, substituted with R^7 and R^8 at the 2-position, and a wavy line at the 3-position.

Structure 6: A benzene ring with a nitrogen atom at the 1-position, substituted with R^7 and R^8 at the 2-position, and a wavy line at the 3-position.

Structure 7: A benzene ring with a nitrogen atom at the 1-position, substituted with R^7 and R^8 at the 2-position, and a wavy line at the 3-position.







Structure 8: A benzene ring with a nitrogen atom at the 1-position, substituted with R^7 and R^8 at the 2-position, and a wavy line at the 3-position.







Structure 9: A benzene ring with a nitrogen atom at the 1-position, substituted with R^7 and R^8 at the 2-position, and a wavy line at the 3-position.

Structure 10: A benzene ring with a nitrogen atom at the 1-position, substituted with R^7 and R^8 at the 2-position, and a wavy line at the 3-position.


Structure 11: A benzene ring with a nitrogen atom at the 1-position, substituted with R^7 and R^8 at the 2-position, and a wavy line at the 3-position.








Structure 12: A benzene ring with a nitrogen atom at the 1-position, substituted with R^7 and R^8 at the 2-position, and a wavy line at the 3-position.







(2)






(3)






wherein one or both of the above rings of said A groups are substituted with 1 to 6 substituents each independently selected from the group consisting of: R^9 groups, provided that when R^9 is R^{13} then R^{13} is not H;

(4)





wherein the above phenyl rings of said A groups are substituted with 1 to 3 substituents each independently selected from the group consisting of: R^9 groups, provided that when R^9 is R^{13} then R^{13} is not H; and

(5)



B is selected from the group consisting of





n is 0 to 6;

p is 1 to 5;


X is O, NH, or S;

Z is 1 to 3;

R^2 is selected from the group consisting of: hydrogen, OH, $-C(O)OH$, $-SH$, $-SO_2NR^{13}R^{14}$, $-NHC(O)R^{13}$, $-NHSO_2NR^{13}R^{14}$, $-NHSO_2R^{13}$, $-NR^{13}R^{14}$, $-C(O)NR^{13}R^{14}$, $-C(O)NHOR^{13}$, $-C(O)NR^{13}OH$, $-S(O_2)OH$, $-OC(O)R^{13}$, an unsubstituted heterocyclic acidic functional group, and a substituted heterocyclic acidic functional group; wherein there are 1 to 6 substituents on said substituted heterocyclic acidic functional group each substituent being independently selected from the group consisting of: R^9


groups, and wherein the heterocyclic acidic functional group is selected from the group consisting of pyrrole, imidazole, triazole, and tetrazole;

each R^3 and R^4 is independently selected from the group consisting of: hydrogen, cyano, halogen, alkyl, alkoxy, cycloalkyl substituted with 1 to 4 alkyl groups wherein each alkyl group is independently selected, unsubstituted cycloalkyl, cycloalkyl substituted with 1 to 4 alkyl groups, $-OH$, $-CF_3$, $-OCF_3$, $-NO_2$, $-C(O)R^{13}$, $-C(O)OR^{13}$, $-C(O)NHR^{17}$, $-C(O)NR^{13}R^{14}$, $-SO_{(t)}NR^{13}R^{14}$, $-SO_{(t)}R^{13}$, $-C(O)NR^{13}OR^{14}$, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl,




wherein there are 1 to 6 substituents on said substituted aryl group and each substituent is independently selected from the group consisting of: R^9 groups; and wherein there are 1 to 6 substituents on said substituted heteroaryl group and each substituent is independently selected from the group consisting of: R^9 groups; or

R^3 is and R^4 taken together with the carbons atoms to which they are bonded to in the the phenyl B substituent



form a fused ring of the formula:



wherein Z^1 or Z^2 is an unsubstituted or substituted saturated heterocyclic ring, said ring Z^1 or Z^2 optionally containing one additional heteroatom selected from the group consisting of: O, S and NR^{18} ; wherein there are 1 to 3 substituents on said ring Z^1 or Z^2 , and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, amino, $-C(O)OR^{15}$, $-C(O)NR^{15}R^{16}$,

$-\text{SO}_t\text{NR}^{15}\text{R}^{16}$, $-\text{C}(\text{O})\text{R}^{15}$, $-\text{SO}_2\text{R}^{15}$ provided that R^{15} is not H, $-\text{NHC}(\text{O})\text{NR}^{15}\text{R}^{16}$, $-\text{NHC}(\text{O})\text{OR}^{15}$, halogen, and a heterocycloalkenyl group;

each R^5 and R^6 are the same or different and are independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, $-\text{CF}_3$, $-\text{OCF}_3$, $-\text{NO}_2$, $-\text{C}(\text{O})\text{R}^{13}$, $-\text{C}(\text{O})\text{OR}^{13}$, $-\text{C}(\text{O})\text{NR}^{13}\text{R}^{14}$, $-\text{SO}_{(t)}\text{NR}^{13}\text{R}^{14}$, $-\text{C}(\text{O})\text{NR}^{13}\text{OR}^{14}$, cyano, unsubstituted or substituted aryl, and unsubstituted or substituted heteroaryl group; wherein there are 1 to 6 substituents on said substituted aryl group and each substituent is independently selected from the group consisting of: R^9 groups; and wherein there are 1 to 6 substituents on said substituted heteroaryl group and each substituent is independently selected from the group consisting of: R^9 groups;

each R^7 and R^8 is independently selected from the group consisting of: H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroarylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, $-\text{CO}_2\text{R}^{13}$, $-\text{CONR}^{13}\text{R}^{14}$, alkynyl, alkenyl, and cycloalkenyl; and wherein there are one or more substituents on said substituted R^7 and R^8 groups, wherein each substituent is independently selected from the group consisting of:


- a) halogen,
- b) $-\text{CF}_3$,
- c) $-\text{COR}^{13}$,
- d) $-\text{OR}^{13}$,
- e) $-\text{NR}^{13}\text{R}^{14}$,
- f) $-\text{NO}_2$,
- g) $-\text{CN}$,
- h) $-\text{SO}_2\text{OR}^{13}$,
- i) $-\text{Si}(\text{alkyl})_3$, wherein each alkyl is independently selected,
- j) $-\text{Si}(\text{aryl})_3$, wherein each ~~alkyl~~ aryl is independently selected,
- k) $-(\text{R}^{13})_2\text{R}^{14}\text{Si}$, wherein each R^{13} is independently selected,
- l) $-\text{CO}_2\text{R}^{13}$,
- m) $-\text{C}(\text{O})\text{NR}^{13}\text{R}^{14}$,

- n) $-\text{SO}_2\text{NR}^{13}\text{R}^{14}$,
- o) $-\text{SO}_2\text{R}^{13}$,
- p) $-\text{OC}(\text{O})\text{R}^{13}$,
- q) $-\text{OC}(\text{O})\text{NR}^{13}\text{R}^{14}$,
- r) $-\text{NR}^{13}\text{C}(\text{O})\text{R}^{14}$, and
- s) $-\text{NR}^{13}\text{CO}_2\text{R}^{14}$;

R^{8a} is selected from the group consisting of: hydrogen, alkyl, cycloalkyl and cycloalkylalkyl;

each R^9 is independently selected from the group consisting of:

- a) $-\text{R}^{13}$,
- b) halogen,
- c) $-\text{CF}_3$,
- d) $-\text{COR}^{13}$,
- e) $-\text{OR}^{13}$,
- f) $-\text{NR}^{13}\text{R}^{14}$,
- g) $-\text{NO}_2$,
- h) $-\text{CN}$,
- i) $-\text{SO}_2\text{R}^{13}$,
- j) $-\text{SO}_2\text{NR}^{13}\text{R}^{14}$,
- k) $-\text{NR}^{13}\text{COR}^{14}$,
- l) $-\text{CONR}^{13}\text{R}^{14}$,
- m) $-\text{NR}^{13}\text{CO}_2\text{R}^{14}$,
- n) $-\text{CO}_2\text{R}^{13}$,
- o)



- p) alkyl substituted with one or more $-\text{OH}$ groups,
- q) alkyl substituted with one or more $-\text{NR}^{13}\text{R}^{14}$ group, and
- r) $-\text{N}(\text{R}^{13})\text{SO}_2\text{R}^{14}$;

each R^{10} and R^{11} is independently selected from the group consisting of R^{13} , halogen, $-CF_3$, $-OCF_3$, $-NR^{13}R^{14}$, $-NR^{13}C(O)NR^{13}R^{14}$, $-OH$, $-C(O)OR^{13}$, $-SH$, $-SO_{(t)}NR^{13}R^{14}$, $-SO_2R^{13}$, $-NHC(O)R^{13}$, $-NHSO_2NR^{13}R^{14}$, $-NHSO_2R^{13}$, $-C(O)NR^{13}R^{14}$, $-C(O)NR^{13}OR^{14}$, $-OC(O)R^{13}$ and cyano;

R^{12} is selected from the group consisting of: hydrogen, $-C(O)OR^{13}$, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkylalkyl, and unsubstituted or substituted heteroarylalkyl group; wherein there are 1 to 6 substituents on the substituted R^{12} groups and each substituent is independently selected from the group consisting of: R^9 groups;

each R^{13} and R^{14} is independently selected from the group consisting of: H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroarylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heterocyclic, unsubstituted or substituted fluoroalkyl, and unsubstituted or substituted heterocycloalkylalkyl (wherein "heterocycloalkyl" means heterocyclic); wherein there are 1 to 6 substituents on said substituted R^{13} and R^{14} groups and each substituent is independently selected from the group consisting of: alkyl, $-CF_3$, $-OH$, alkoxy, aryl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, $-N(R^{40})_2$, $-C(O)OR^{15}$, $-C(O)NR^{15}R^{16}$, $-S(O)_tNR^{15}R^{16}$, $-C(O)R^{15}$, $-SO_2R^{15}$ provided that R^{15} is not H, halogen, and $-NHC(O)NR^{15}R^{16}$; or

R^{13} and R^{14} taken together with the nitrogen they are attached to in the groups $-C(O)NR^{13}R^{14}$ and $-SO_2NR^{13}R^{14}$ form an unsubstituted or substituted saturated heterocyclic ring, said ring optionally containing one additional heteroatom selected from the group consisting of: O, S and NR^{18} ; wherein there are 1 to 3 substituents on the substituted cyclized R^{13} and R^{14} groups and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, amino, $-C(O)OR^{15}$, $-C(O)NR^{15}R^{16}$, $-SO_tNR^{15}R^{16}$, $-C(O)R^{15}$, $-SO_2R^{15}$ provided that R^{15} is not H, $-NHC(O)NR^{15}R^{16}$, $-NHC(O)OR^{15}$, halogen, and a heterocycloalkenyl group;

each R^{15} and R^{16} is independently selected from the group consisting of: H, alkyl, aryl, arylalkyl, cycloalkyl and heteroaryl;

R^{17} is selected from the group consisting of: $-\text{SO}_2\text{alkyl}$, $-\text{SO}_2\text{aryl}$, $-\text{SO}_2\text{cycloalkyl}$, and $-\text{SO}_2\text{heteroaryl}$;

R^{18} is selected from the group consisting of: H, alkyl, aryl, heteroaryl, $-\text{C}(\text{O})R^{19}$, $-\text{SO}_2R^{19}$ and $-\text{C}(\text{O})\text{NR}^{19}R^{20}$;

each R^{19} and R^{20} is independently selected from the group consisting of: alkyl, aryl and heteroaryl;

R^{30} is selected from the group consisting of: alkyl, cycloalkyl, $-\text{CN}$, $-\text{NO}_2$, or $-\text{SO}_2R^{15}$ provided that R^{15} is not H;

each R^{31} is independently selected from the group consisting of: unsubstituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl and unsubstituted or substituted cycloalkyl; wherein there are 1 to 6 substituents on said substituted R^{31} groups and each substituent is independently selected from the group consisting of: alkyl, halogen and $-\text{CF}_3$;


each R^{40} is independently selected from the group consisting of: H, alkyl and cycloalkyl;

g is 1 or 2; and


t is 0, 1 or 2.

2. (CURRENTLY AMENDED) The compound of claim 1 wherein A is selected from the group consisting of:


(1) unsubstituted or substituted:



(2) — substituted:




3. (ORIGINAL) The compound of Claim 1 wherein substituent A is:




wherein the furan ring is unsubstituted or substituted with 1 or 2 alkyl groups wherein each alkyl group is independently selected, R^7 is selected from the group consisting of: $-CF_3$, alkyl and cycloalkyl, and R^8 is H.


4. (ORIGINAL) The compound of Claim 1 wherein substituent A is:




wherein the furan ring is substituted with 1 or 2 alkyl groups independently selected from the group consisting of methyl, ethyl and isopropyl, R^7 is selected from the group consisting of: ethyl, isopropyl and t-butyl, and R^8 is H.

5. (CURRENTLY AMENDED) The compound of Claim 1 wherein A is selected from the group consisting of:












6. (CURRENTLY AMENDED) The compound of claim 1 wherein A is selected from the group consisting of:




7. (ORIGINAL) The compound of Claim 1 wherein substituent A is selected from the group consisting of:




8. (ORIGINAL) The compound of Claim 1 wherein B is selected from the group consisting of:




9. (ORIGINAL) The compound of Claim 1 wherein B is selected from the group consisting of:




10. (ORIGINAL) The compound of Claim 1 wherein B is selected from the group consisting of:




11. (ORIGINAL) The compound of Claim 1 wherein B is selected from the group consisting of:



12. (ORIGINAL) The compound of Claim 1 wherein B is




13. (ORIGINAL) The compound of Claim 1 wherein B is:




wherein R^2 is $-OH$.

14. (ORIGINAL) The compound of Claim 1 wherein B is:



wherein R^2 is $-OH$, and R^{13} and R^{14} are independently selected from the group consisting of H and alkyl.

15. (ORIGINAL) The compound of Claim 1 wherein B is




16. (ORIGINAL) The compound of Claim 15 wherein R^{11} is H.

17. (ORIGINAL) The compound of Claim 16 wherein R^2 is $-OH$.

18. (ORIGINAL) The compound of Claim 17 wherein R^3 is $-C(O)NR^{13}R^{14}$.


19. (ORIGINAL) The compound of Claim 17 wherein R^3 is $-S(O)_tNR^{13}R^{14}$.

20. (ORIGINAL) The compound of Claim 1 wherein B is:




wherein R^2 is $-\text{OH}$, R^3 is $-\text{C}(\text{O})\text{NR}^{13}\text{R}^{14}$, R^{11} is H or methyl, and R^{13} and R^{14} are independently selected from the group consisting of: H, alkyl, unsubstituted cycloalkyl, substituted cycloalkyl, unsubstituted heteroaryl and substituted heteroaryl.

21. (ORIGINAL) The compound of Claim 1 wherein B is:




wherein R^2 is $-\text{OH}$, R^3 is $-\text{S}(\text{O})_t\text{NR}^{13}\text{R}^{14}$, R^{11} is H or methyl, and R^{13} and R^{14} are independently selected from the group consisting of H, alkyl, unsubstituted cycloalkyl and substituted cycloalkyl.

22. (ORIGINAL) The compound of Claim 1 wherein B is:




23. (ORIGINAL) The compound of Claim 22 in R^{11} is H.
24. (ORIGINAL) The compound of Claim 23 wherein R^2 is $-\text{OH}$.
25. (ORIGINAL) The compound of Claim 24 wherein R^3 is $-\text{C}(\text{O})\text{NR}^{13}\text{R}^{14}$.
26. (ORIGINAL) The compound of Claim 24 wherein R^3 is $-\text{S}(\text{O})_t\text{NR}^{13}\text{R}^{14}$.

27. (ORIGINAL) The compound of Claim 1 wherein B is:



wherein R² is -OH, R³ is -C(O)NR¹³R¹⁴, R¹¹ is H, and R¹³ and R¹⁴ are independently selected from the group consisting of: H, alkyl, unsubstituted heteroaryl and substituted heteroaryl.

28. (ORIGINAL) The compound of Claim 1 wherein B is:





wherein R² is -OH, R³ is -S(O)_tNR¹³R¹⁴, R¹¹ is H, and R¹³ and R¹⁴ are independently selected from the group consisting of H and alkyl.

29. (CURRENTLY AMENDED) The compound of Claim 1 wherein:


(1) substituent A in formula IA is selected from the group consisting of:

(a)




wherein the above rings are unsubstituted, or the above rings are substituted with 1 to 3 substituents independently selected from the group consisting of: F, Cl, Br, alkyl, cycloalkyl, and $-\text{CF}_3$; R^7 is selected from the group consisting of: H, $-\text{CF}_3$, $-\text{CF}_2\text{CH}_3$, methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and R^8 is H; and

(b)



~~wherein the above ring is substituted with 1 to 3 substituents independently selected from the group consisting of: F, Cl, Br, alkyl, cycloalkyl, and $-\text{CF}_3$; R^7 is selected from the group consisting of: H, $-\text{CF}_3$, $-\text{CF}_2\text{CH}_3$, methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and R^8 is H; and~~

(2) substituent B in formula IA is selected from the group consisting of:



wherein:

R^2 is selected from the group consisting of: H, OH, $-NHC(O)R^{13}$ and $-NHSO_2R^{13}$;

R^3 is selected from the group consisting of: $-C(O)NR^{13}R^{14}$, $-SO_2NR^{13}R^{14}$, $-NO_2$, cyano, and $-SO_2R^{13}$;

R^4 is selected from the group consisting of: H, $-NO_2$, cyano, alkyl, halogen and $-CF_3$;

R^5 is selected from the group consisting of: H, $-CF_3$, $-NO_2$, halogen and cyano;


R^6 is selected from the group consisting of: H, alkyl and $-CF_3$;


R^{11} is selected from the group consisting of: H, halogen and alkyl; and

each R^{13} and R^{14} is independently selected from the group consisting of: H, unsubstituted alkyl.


30. (CURRENTLY AMENDED) The compound of Claim 1 wherein:

(1) substituent A in formula IA is selected from the group consisting of:





(2) substituent B in formula IA is selected from the group consisting of:



wherein:

R^2 is $-OH$;

R^3 is selected from the group consisting of: $-SO_2NR^{13}R^{14}$ and $-CONR^{13}R^{14}$;

R^4 is selected from the group consisting of: H, Br, $-CH_3$, ethyl and $-CF_3$;


R^5 is selected from the group consisting of: H and cyano;

R^6 is selected from the group consisting of: H, $-CH_3$ and $-CF_3$;


R^{11} is H; and

R^{13} and R^{14} are independently selected from the group consisting of H and methyl.


31. (ORIGINAL) The compound of Claim 1 wherein substituent A is selected from the group consisting of:




and substituent B is selected from the group consisting of:



32. (ORIGINAL) The compound of Claim 1 wherein substituent A is selected from the group consisting of:



and substituent B is selected from the group consisting of:



33. (ORIGINAL) The compound of Claim 1 wherein g is 1.

34. (ORIGINAL) The compound of Claim 1 wherein g is 2.

35. (ORIGINAL) The compound of Claim 31 wherein g is 1.


36. (ORIGINAL) The compound of Claim 32 wherein g is 2.













37. (PREVIOUSLY PRESENTED) A sodium, potassium, calcium, aluminum, gold, silver, N-methylglucamine, hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, or methanesulfonic salt of a compound of Claim 1.













38. (ORIGINAL) A sodium salt of a compound of Claim 1.











39. (ORIGINAL) A calcium salt of a compound of Claim 1.













40. (CURRENTLY AMENDED) A compound selected from the group consisting of:

















































































[[(a12)]]

[[,]]




pharmaceutically acceptable salts thereof, and pharmaceutically acceptable solvates thereof.


41. (CURRENTLY AMENDED) The compound of Claim 40 selected from the group consisting of:




(a1)




(a2)




(a3)




(a4)




(a5)




(a6)




(a7)




(a8)




(a9)











(a10)




(a11)




(a12)







(a21)




(a22)




(a23)




(a24)




(a25)




(a26)




(a27)




(a28)




(a29)




(a30)




(a31)




(a32)




(a33)




(a34)




(a35)




(a36)




(a37)




(a38)




(a39)




(a40)




(a41)




(a41)




(a42)




(a43)




(a44)




(a45)




(a46)




(a47)




(a48)




(a49)



(a50)




(a51)




(a52)

pharmaceutically acceptable salts thereof, and pharmaceutically acceptable solvates thereof.


42. (PREVIOUSLY PRESENTED) The compound of Claim 41 selected from the group consisting of compounds of the formula:




(a20)




(a21)




(a22)




(a23)




(a24)




(a25)




(a26)




(a27)




(a28)




(a29)




(a30)




(a31)




(a32)




(a33)




(a34)




(a35)




(a36)




(a37)




(a38)




(a39)




(a40)




(a41)




(a41)




(a42)




(a43)




(a44)




(a45)




(a46)




(a47)




(a48)




(a49)



(a50)




(a51)



(a52)


the pharmaceutically acceptable salts thereof, and the pharmaceutically acceptable solvates thereof.

43. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

44. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

45. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

46. (ORIGINAL) The compound of Claim 42 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

47. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

48. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

49. (ORIGINAL) The compound of Claim 41 having the formula:



or a pharmaceutically acceptable salt or solvate thereof.


50. (ORIGINAL) The compound of Claim 41 having the formula:



or a pharmaceutically acceptable salt or solvate thereof.


51. Canceled (without prejudice).

52. (ORIGINAL) The compound of Claim 41 having the formula:



or a pharmaceutically acceptable salt or solvate thereof.


53. (ORIGINAL) The compound of Claim 41 having the formula:



or a pharmaceutically acceptable salt or solvate thereof.


54. Canceled (without prejudice).

55. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

56. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

57. (ORIGINAL) The compound of Claim 41 having the formula:



or a pharmaceutically acceptable salt or solvate thereof.


58. (ORIGINAL) The compound of Claim 41 having the formula:



or a pharmaceutically acceptable salt or solvate thereof.


59. Canceled (without prejudice).

60. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

61. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

62. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

63. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

64. (PREVIOUSLY PRESENTED) The compound of Claim 40 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

65. (PREVIOUSLY PRESENTED) The compound of Claim 40 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

66. (PREVIOUSLY PRESENTED) The compound of Claim 40 having the formula:



or a pharmaceutically acceptable salt or solvate thereof.

67. (PREVIOUSLY PRESENTED) The compound of Claim 40 having the formula:



or a pharmaceutically acceptable salt or solvate thereof.

70. (ORIGINAL) A pharmaceutical composition comprising at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with a pharmaceutically acceptable carrier.

71. (ORIGINAL) A pharmaceutical composition comprising at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, and at least one other agent, medicament, antibody and/or inhibitor for treating a chemokine mediated disease, in combination with a pharmaceutically acceptable carrier.

72. (ORIGINAL) A pharmaceutical composition comprising at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof, in combination with a pharmaceutically acceptable carrier.

73. (ORIGINAL) A pharmaceutical composition comprising at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof, and at least one other agent, medicament, antibody and/or inhibitor for treating a chemokine mediated disease, in combination with a pharmaceutically acceptable carrier.

86. CANCELED (without prejudice).

87. CANCELED (without prejudice).

88. CANCELED (without prejudice).

89. CANCELED (without prejudice).

90. CANCELED (without prejudice).

91. CANCELED (without prejudice).

92. CANCELED (without prejudice).

93. CANCELED (without prejudice).

112. CANCELED (without prejudice).

113. CANCELED (without prejudice).

114. CANCELED (without prejudice).

115. CANCELED (without prejudice).

116. CANCELED (without prejudice).



117. CANCELED (without prejudice).









118. CANCELED (without prejudice).










119. CANCELED (without prejudice).






132. CANCELED (without prejudice)







133. (NEW) A compound selected from the group consisting of:










































































































































































































































































b





















































and

